Non-invasive in vivo imaging of transplant function

Progress in Brain Research

Volumn 127, Issue , 2000, Pages 321-332

  Brooks, David J ^a   Piccini, Paola ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLSPIPERONE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ANTIPARKINSON AGENT; CARBON 11; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; FLUORODEOXYGLUCOSE F 18; IODINE 123; LEVODOPA; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; RACLOPRIDE;

BRAIN BLOOD FLOW; BRAIN METABOLISM; CAUDATE NUCLEUS; CLINICAL ARTICLE; DISEASE DURATION; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; GRAFT SURVIVAL; HUMAN; HUNTINGTON CHOREA; NERVE TRANSPLANTATION; NEUROLOGIC DISEASE; NEURORADIOLOGY; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RECEPTOR BINDING; REVIEW;

EID: 0034589073     PISSN: 00796123     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6123(00)27015-5     Document Type: Article

References (68)

1. Andrews, T.C., Weeks, R.A., Turjanski, N., Gunn, R., Sahakian, B., Hodges, J., Rosser, A., Wood, N. and Brooks, D.J. (1999) Huntington's disease progression: PET and clinical observations. Brain, 122: 2353-2363.
2. 2-receptors. Neurology, 44: 1325-1329.
3. Antonini, A., Leenders, K.L., Spiegel, R., Meier, D., Vontobel, P., Weigell Weber, M., Sanchez Pernaute, R., De Yebenes, J.G., Boesiger, P., Weindel, A. and Maguire, R.P. (1996) Striatal glucose metabolism and dopamine D-2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain, 119: 2085-2095.
4. Berent, S., Giordani, B., Lehtinen, S., Markel, D., Penney, J.B., Buchtel, H.A., Starosta Rubinstein, S., Hichwa, R. and Young, A.B. (1988) Positron emission tomographic scan investigations of Huntington's disease - Cerebral metabolic correlates of cognitive function. Ann. Neurol., 23: 541-546.
5. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 62: 133-140.
6. 18F-dopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Ann. Neurol., 28: 547-555.
7. 11C-raclopride and PET. Ann. Neurol., 31: 184-192.
8. 2 receptor imaging with SPECT: Studies in different neuropsychiatric disorders. J. Cereb. Blood Flow Metab., 11: 220-228.
9. Ellias, S.A., Palmer, E.P., Kott, H.S., Thomas, C., Isacson, O., Schumacher, J. and Fink, J.S. (1998) Transplantation of fetal porcine ventral mesencephalic cells for treatment of Parkinson's disease: One year safety and efficacy results. Neurology, 50(Suppl. 4): A80.
10. Fearnley, J.M. and Lees, A.J. (1991) Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain, 114: 2283-2301.
11. 18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate. J. Neurochem., 48: 1077-1082.
12. Freed, C.R., Breeze, R.E., Rosenberg, N.L., Schneck, S.A., Kriek, E., Qi, J.-X., Lone, T., Zhang, Y.-B., Snyder, J.A., Wells, T.H., Ramig, L.O., Thompson, L., Mazziotta, J.C., Huang, S.C., Grafton. S.T., Brooks, D., Sawle, G., Schroter, G. and Ansari, A.A. (1992) Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. New Engl. J. Med., 327: 1549-1555.
13. Freeman, T.B., Olanow, C.W., Hauser, R.A., Nauert, G.M., Smith, D.A., Borlongan, C.V., Sanberg, P.R., Holt, D.A., Kordower, J.H., Vingerhoets, F.J.G., Snow, B.J., Calne, D.B. and Gauger, L.L. (1995) Bilateral fetal nigral transplantation into the post-commissural putamen as a treatment for Parkinson's disease: Six months follow-up. Ann. Neurol., 38: 379-388.
14. Fricker, R.A., Torres, E.M., Hume, S.P., Myers, R., Opacka-Juffrey, J., Ashworth, S., Brooks, D.J. and Dunnett, S,B. (1997) The effects of donor stage on the survival and function of embryonic striatal grafts in the adult rat brain, II. Correlation between positron emission tomography and reaching behaviour. Neuroscience, 79: 711-722.
15. Friston, K.J., Frith, C.D., Liddle, P.F., Dolan, R.J., Lammertsma, A.A. and Frackowiak, R.S.J. (1990) The relationship between global and local changes in PET scans. J. Cereb. Blood Flow Metab., 10: 458-466.
16. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann. Neurol., 34: 423-431.
17. Garnett, E.S., Nahmias, C. and Firnau, G. (1984) Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography. Can. J. Neurol. Sci., 11: 174-179.
18. Grafton, S.T., Mazziotta, J.C., Pahl, J.J., St. George-Hyslop, P., Haines, J.L., Gusella, J., Hoffman, J.M., Baxter, L.R. and Phelps, M.E. (1990) A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease. Ann. Neurol., 28: 614-621.
19. Grafton, S.T., Mazziotta, J.C., Pahl, J.J., St. George Hyslop, P., Haines, J.L., Gusella, J., Hoffman, J.M., Baxter, L.R. and Phelps, M.E. (1992) Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. Arch. Neurol., 49: 1161-1167.
20. 2 receptor density in Parkinsonian brain is constant for duration of disease, age, and duration of L-dopa therapy. Adv. Neurol., 46: 51-57.
21. IIC]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: Implications for the symptomatic threshold. Neurology, 48: 1578-1583.
22. Hagell, P., Schrag, A.E., Piccini, P., Jahanshahi, M., Brown, R., Odin, P., Wenning, G., Morrish, P., Rehncrona, S., Widner, H., Brundin, P., Rothwell, J.C., Gustavii, B., Björklund, A., Brooks, D.J., Marsden, C.D., Quinn, N.P. and Lindvall, O. (1999) Sequential bilateral transplantation in Parkinson's disease: Effects of the second graft. Brain, 122: 1121-1132.
23. 11C-N-methyl-spiperone. Acta Neurol. Scand., 75: 87-94.
24. Hayden, M.R., Martin, W.R.W., Stoessl, A.J., Clark, C., Hollenberg, S., Adam, M.J., Ammann, W. and Harrop, R. (1986) Positron emission tomography in the early diagnosis of Huntington's disease. Neurology, 36: 888-894.
25. Hayden, M.R., Hewitt, J., Martin, W.R.W., Clark, C. and Amman, A. (1987) Studies in persons at risk for Huntington's disease. New Engl. J. Med., 317: 382-383.
26. Jahanshabi, M., Jenkins, I.H., Brown, R.G., Marsden, C.D., Passingham, R.E. and Brooks, D.J. (1995) Self-initiated versus externally triggered movements: Measurements of regional cerebral blood flow and movement-related potentials in normals and Parkinson's disease. Brain, 118: 913-933.
27. Jenkins, I.H., Fernandez, W., Playford, E.D., Lees, A.J., Frackowiak, R.S.J., Passingham, R.E. and Brooks, D.J. (1992) Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. Ann. Neurol., 32: 749-757.
28. 1 receptor number - A sensitive PET marker for early brain degeneration in Huntington's disease. Eur. Arch. Psychiatry Clin. Neurosci., 243: 249-255.
29. Kopyov, O.V., Jacques, S., Lieberman, A., Duma, C.M. and Eagles, K.S. (1998) Safety of intrastriatal neurotransplantation for Huntington's disease patients. Exp. Neurol., 149: 97-108.
30. Kordower, J.H., Freeman, T.B., Snow, B.J., Vingerhoets, F.J.G., Mufson, E.J., Sanberg, P.R., Hauser, R.A., Smith, D.A., Nauert. G.M., Perl, D.P. and Olanow, C.W. (1995) Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. New Engl. J. Med., 332: 1118-1124.
31. Kuhl, D.E., Phelps, M.E., Markham, C.H., Metter, E.J., Riege, W.H. and Winter, E.J. (1982) Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scans. Ann. Neurol., 12: 425-434.
32. Kuhl, D.E., Metter, E.J., Riege, W.H. and Markham, C.H. (1984) Patterns of cerebral glucose utilisation in Parkinson's disease and Huntington's disease. Ann. Neurol., 15(Suppl.): S119-S125.
33. Kuwert, T., Lange, H.W., Langen, K.J., Herzog, H., Aulich, A. and Feinendegen, L.E. (1990) Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. Brain, 113: 1405-1423.
34. Leenders, K.L., Herold, S., Palmer, A.J., Turton, N., Quinn, N., Jones, T., Frackowiak, R.S.J. and Marsden, C.D. (1985) Human cerebral dopamine system measured in vivo using PET. J. Cereb. Blood Flow Metab., 5(Suppl.): S157-S158.
35. Leenders, K.L., Frackowiak, R.S.J., Quinn, N. and Marsden, C.D. (1986a) Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography. Mov. Disord., 1: 69-77.
36. Leenders, K.L., Palmer, A., Turton, D., Quinn, N., Firnau, G., Garnett, S., Nahmias, C., Jones, T. and Marsden, C.D. (1986b) DOPA uptake and dopamine receptor binding visualized in the human brain in vivo. In: S. Fahn, C.D. Marsden, P. Jenner and P. Teychenne (Eds.), Recent Developments in Parkinson's Disease. Raven Press, New York, pp. 103-113.
37. Leenders, K.L., Palmer, A.J., Quinn, N., Clark, J.C., Firnau, G., Garnett, E.S., Nahmias, C., Jones, T. and Marsden, C.D. (1986c) Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J. Neurol. Neurosurg. Psychiatry, 49: 853-860.
38. 11C-raclopride. Mov. Disord., 7(Suppl. 1): 141.
39. Lindvall, O., Widner, H., Rehncrona, S., Brundin, P., Odin, P., Gustavii, B., Frackowiak, R.S.J., Leenders, K.L., Sawle, G.V., Rothwell, J.C., Björklund, A. and Marsden, C.D. (1992) Transplantation of fetal dopamine neurons in Parkinson's disease: One-year clinical and neurophysiological observations in two patients with putaminal implants. Ann. Neurol., 31: 155-165.
40. Lindvall, O., Sawle, G., Widner, H., Rothwell, J.C., Björklund, A., Brooks, D., Brundin, P., Frackowiak, R., Marsden, C.D., Odin, P. and Rehncrona, S. (1994) Evidence for long term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann. Neurol., 35: 172-180.
41. Marek, K., Seibyl, J.P., Zoghbi, S.S., Zeaponce, Y., Baldwin, R.M., Fussell, B., Charney, D.S., Vandyck, C., Hoffer, P.B. and Innis, R.B. (1996) [I-123] beta-CIT SPECT imaging demonstrates bilateral loss of dopamine transporters in hemiparkinsons disease. Neurology, 46: 231-237.
42. 123I-CIT: Assessment of progression in Parkinson's disease. Neurology, 48(Suppl. 2): A207.
43. Martin, W.R.W., Stoessl, A.J. and Adam, M.J. et al. (1986) Positron emission tomography in Parkinson's disease: Glucose and dopa metabolism. Adv. Neurol., 45: 95-98.
44. 18F]dopa PET findings in early Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 59: 597-600.
45. 18F]dopa PET and clinical study of the rate of progression in Parkinson's disease. Brain, 119: 585-591.
46. 18F]dopa PET. J. Neurol. Neurosurg. Psychiatry, 64: 314-319.
47. Nahmias, C., Garnett, E.S., Firnau, G. and Lang, A. (1985) Striatal dopamine distribution in Parkinsonian patients during life. J. Neurol. Sci., 69: 223-230.
48. Philpott, L.M., Kopyov, O.V., Lee, A.J., Jacques, S., Duma, C.M., Caine, S., Yang, M. and Eagle, K.S. (1997) Neuropsychological functioning following fetal striatal transplantation in Huntington's chorea: Three case presentations. Cell Transplant., 6: 203-212.
49. Playford, E.D., Jenkins, I.H., Passingham, R.E., Nutt, J., Frackowiak, R.S.J. and Brooks, D.J. (1992) Impaired mesial frontal and putamen activation in Parkinson's disease: A PET study. Ann. Neurol., 32: 151-161.
50. 18F-fluorodopa PET in early Parkinson's disease. Neurology, 46(Suppl.): A452.
51. Rascol, O., Sabatini, U., Chollet, F., Celsis, P., Montastruc, J.-L., Marc-Vergnes, J.-P. and Rascol, A. (1992) Supplementary and primary sensory motor area activity in Parkinson's disease. Regional cerebral blood flow changes during finger movements and effects of apomorphine. Arch. Neurol., 49: 144-148.
52. Rascol, O., Sabatini, U., Chollet, F., Fabre, N., Senard, J.M., Montastruc. J.L., Celsis, P., Marcvergnes, J.P. and Rascol, A. (1994) Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa. J. Neurol. Neurosurg. Psychiatry, 57: 567-571.
53. 18F]fluorodopa uptake in five grafted parkinsonian patients. Ann. Neurol., 38: 580-588.
54. 2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov. Disord., 5: 55-59.
55. 2 receptor changes during the progression of early Parkinson's disease. Mov. Disord., 8: 134-138.
56. 18F]-6-L-Fluorodopa studies in two patients with putaminal implants. Ann. Neurol., 31: 166-173.
57. 123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de-novo parkinsonism. Neurology, 42: 556-561.
58. 123I-IPT and SPECT. Neurology, 48(Suppl. 2): A208.
59. 2 receptors in Parkinson's disease and striato-nigral degeneration determined by positron emission tomography. In: T. Nagatsu, A. Fisher and M. Yoshida (Eds.), Basic, Clinical, and Therapeutic Advances of Alzheimer's and Parkinson's Diseases, Vol 2. Plenum Press, New York, pp. 107-110.
60. St Hillaire, M., Shannon, K., Schumacher, J., Starr, P., Penn, R., Han Horne, C., Isaacson, O, and Fink, J.S. (1998) Transplantation of fetal porcine striatal cells in Huntington's disease: Preliminary safety and efficacy results. Neurology, 50(Suppl. 4): A80.
61. Turjanski, N., Lees, A.J. and Brooks, D.J. (1997) PET studies on striatal dopaminergic receptor binding in drug naive and L-dopa treated Parkinson's disease patients with and without dyskinesia. Neurology, 49: 717-723.
62. Vingerhoets, F.J.G., Snow, B.J., Lee, C.S., Schulzer, M., Mak, E. and Calne, D.B. (1994) Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann. Neurol., 36: 759-764.
63. 2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann. Neurol., 40: 49-54.
64. Wenning, G.K., Odin, P., Morrish, P.K., Rehncrona, S., Widner, H., Brundin, P., Rothwell, J.C., Brown, R., Gustavii, B., Hagell, P., Jahanshahi, M., Sawle, G.V., Björklund, A., Brooks, D.J., Marsden, C.D., Quinn, N.P. and Lindvall, O. (1997) Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann. Neurol., 42: 95-107.
65. Widner, H., Tetrud, J., Rehncrona, S., Snow, B., Brundin, P., Gustavii, B., Björklund, A., Lindvall, O. and Langston, J.W. (1992) Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). New Engl. J. Med., 327: 1556-1563.
66. 18F]fluoroethylspiperone: Findings in disorders related to the dopaminergic system. J. Neural Transm., 81: 195-213.
67. Wong, D.F., Links, J.M., Wagner, H.N.J., Folstein, S.E., Suneja, S., Dannals, R.F., Ravert, H.T., Wilson, A.A., Tune, L.E., Pearlson, G., Folstein, M.F., Bice, A. and Kuhar, N.J. (1985) Dopamine and serotonin receptors measured in-vivo in Huntington's disease with C-11 N-methylspiperone PET imaging. J. Nucl. Med., 26: P107.
68. Young, A.B., Penney, J.B., Starosta-Rubinstein, S., Markel, D.S., Berent, S., Giordani, B. and Ehrenkaufer, R. (1986) PET scan investigations of Huntington's disease: Cerebral metabolic correlates of neurological features and functional decline. Ann. Neurol., 20: 296-303.